Katalin Karikó and Drew Weissman found a way to rewrite those messages—changing one chemical letter to prevent the body from panicking over the unfamiliar code. That made RNA readable and safe. In Canada, Pieter Cullis’s team perfected the next step: wrapping the RNA in tiny fat bubbles—lipid nanoparticles—so they could slip into cells like stealth couriers.
It wasn’t metaphor. It was architecture.
Soon, RNA was powering vaccines, gene silencers, and even CRISPR, the gene-editing scissors delivered as code. In Boston, researchers used RNA to silence a rogue liver protein that caused hereditary amyloidosis. In New York, scientists at Sloan Kettering began decoding tumors into personalized vaccine blueprints—one patient at a time. In California, a child with sickle cell disease had her blood stem cells edited using Cas9 mRNA.
“My body doesn’t scream anymore,” she said during a UCSF press call. “It just breathes.”
RNA wasn’t hype anymore. It was infrastructure.
Which is why the silence in the NIH cafeteria felt jarring.
Former U.S. Surgeon General Jerome Adams had already warned in The Washington Post that slashing funding for mRNA was “biodefense malpractice.” Public health coalitions echoed the alarm, calling the pivot a retreat from the fastest platform in pandemic history.
Weeks later, the numbers caught up with the warnings.
$1.2 billion. Canceled. At least $500 million in HHS mRNA projects were canceled, plus a separate $766 million Moderna bird-flu contract terminated.
HHS’s official statement framed it bluntly: these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. The funding, they said, would shift to more “durable” platforms.
Critics called it a strategic correction. Supporters of the cut, including HHS Secretary Robert F. Kennedy Jr., argued that traditional vaccine types had fewer unknowns. But Adams and others countered that pulling funding midstream risked not just data loss—but brain drain.
Bhattacharya, a controversial figure elevated to NIH director in 2025 after years of polarizing pandemic commentary and frequent clashes with mainstream public health officials, defended the realignment in budget hearings.
“It’s like cutting the fire hose in half because the first five gallons didn’t put out the whole fire,” he said.
But while officials sparred in hearings, researchers saw the impact in real time.
Dr. Udo Okafor trained at MIT and led a team developing a self-amplifying RNA flu vaccine at the NIH. By April, his lab was shuttered. Grants frozen. Samples shelved.
“I can work in Lagos or in Munich,” he said. “They’re building. Here, we’re pausing.”
“You can’t lead the future by defunding it.”
His story is personal, but the numbers suggest it’s systemic.